Clinical Trials Browser

amivantamab × 1 year × Clear all

NCT07042295 2026-03-18

Treatment With Amivantamab and Hyaluronidase or Cetuximab for Advanced Skin Cancer in People With a Weakened Immune System

Phase 2 Recruiting

Locally Recurrent Skin Squamous Cell Carcinoma

NCT04077463 2026-03-17

Chrysalis-2

Phase 1 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT05488314 2026-03-13

METalmark

Phase 1/2 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT05908734 2026-03-13

PolyDamas

Phase 1/2 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT06120140 2026-03-13

COCOON

Phase 2 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT07227025 2026-03-13

KaRAnaSa

Phase 1/2 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT07276399 2026-03-13

OrigAMI-5

Phase 3 Recruiting

Squamous Cell Carcinoma of Head and Neck

NCT06083857 2026-03-11

PhI/II Study of Amivantamab and Tepotinib Combo in MET-altered Non-small Cell Lung Cancer

Phase 1/2 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT04538664 2026-02-25

PAPILLON

Phase 3 Active not recruiting

308 enrolled 12 charts 1 FDA

Carcinoma, Non-Small-Cell Lung

NCT05117931 2026-02-17

A Study of Amivantamab in People With Esophagogastric Cancer

Phase 2 Active not recruiting

Neoplasm Metastasis

NCT05498428 2026-02-13

PALOMA-2

Phase 2 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT07392658 2026-02-06

AMICUTE

Phase 2 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT04988295 2026-02-05

MARIPOSA-2

Phase 3 Active not recruiting

776 enrolled 13 charts 1 FDA

Carcinoma, Non-Small-Cell Lung

NCT04487080 2026-02-04

MARIPOSA

Phase 3 Active not recruiting

1,074 enrolled 13 charts 1 FDA

Carcinoma, Non-Small-Cell Lung

NCT05601973 2026-01-21

AMAZE-lung

Phase 2 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT02609776 2026-01-16

CHRYSALIS

Phase 1 Active not recruiting

751 enrolled 1 FDA

Carcinoma, Non-Small-Cell Lung

NCT06667076 2026-01-16

COPERNICUS

Phase 2 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT05845671 2026-01-14

Amivantamab With Tyrosine Kinase Inhibitors (TKI) for Advanced NSCLC With ALK, ROS1, or RET Alterations

Phase 1/2 Active not recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT04965090 2025-12-18

A Study of Amivantamab and Lazertinib in People With Non-Small Cell Lung Cancer (NSCLC)

Phase 2 Completed

Carcinoma, Non-Small-Cell Lung

NCT05801029 2025-12-09

OSTARA

Phase 2 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT06116682 2025-12-05

Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)

Phase 2 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT05299125 2025-10-01

AMIGO-1

Phase 2 Active not recruiting

Metastatic Non-small Cell Lung Cancers

NCT06632236 2025-04-25

5G-EMERALD

Phase 1 Recruiting

Glioblastoma

NCT05074940 2025-04-10

Amivantamab in Adenoid Cystic Carcinoma

Phase 2 Active not recruiting

Carcinoma, Adenoid Cystic, Salivary Gland Neoplasms

NCT06816992 2025-03-20

ORIC-114 in Combination with Subcutaneous Amivantamab in Patients with EGFR Exon20 Insertion Mutant NSCLC

Phase 1 Recruiting

Other solid neoplasmThoracic

Solid Tumors